Longeveron
Update in progressLGVN (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Longeveron Inc. is a clinical‑stage biotechnology company focused on cellular therapies for aging‑related and life‑threatening conditions in the United States. Its lead product, LOMECEL‑B, is an allogeneic mesenchymal stem cell formulation derived from healthy young donor bone marrow. It is in Phase 3 for hypoplastic left heart syndrome, with prior Phase 2a data in Alzheimer’s disease and Phase 2b for aging frailty. Founded in 2014 and based in Miami, Florida.
Company score
- Sentiment
- 0.36
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.31
- Governance
- 0.12
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.12
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.24
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqCM (NCM)
- LocationUnited States
- CEOMr. Stephen H. Willard Esq.
- Founded2014
- Employees38
- Websitelongeveron.com
Identifiers
- ISINUS54303L2034
- FIGIBBG00YZ6JHT4
- CUSIP54140W107
- CIK0001721484